Stock Ratings / Health Care / LXRX / forecast

ABUS (18) IMMX (29) ANL (47) BCAX (30) ⌘ Pro Terminal →

Lexicon Pharmaceuticals Inc. (LXRX) 12-Month Stock Forecast & Price Target Cone

$1.42 -4.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.41

Lexicon Pharmaceuticals Inc. (LXRX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $658.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LXRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.42 (-4.05% 1D, market cap $658.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LXRX compare to ABUS and IMMX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LXRX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -31.5%. By comparison, ABUS (Arbutus Biopharma Corporation) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M) and IMMX (Immix Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, LXRX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LXRX?

▼

Per LXRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001062822), Lexicon Pharmaceuticals Inc. generated $49.8M in revenue (+729.9% YoY), -$50.3M in net income, and -$67.9M in free cash flow against $185.0M in total assets and $49.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.41 (-0.92%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LXRX)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY LXRX SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (41% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 36 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.65-6.1% Next Q

Q2 (-2Q)

Grade E$1.55-6.5% Next Q

Q3 (-1Q)

Grade E$1.45-2.1% Next Q

Current

Grade E$1.42-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LXRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LXRX currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.87) and Max Pain ($1.49) forces dealer call-delta covering toward $2.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LXRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LXRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LXRX Position Size: $10,000

Shares at $1.42: 7042.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.95

$6,690

$-3,310 (-33.1%)

12M Consensus BaseTarget $1.22

$8,592

$-1,408 (-14.1%)

12M Bull Case BreakoutTarget $2.81

$19,789

+$9,789 (+97.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LXRX)

✓Walkthrough of LXRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LXRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.25%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.48H $1.48L $1.42C $1.42VOL 1.77M

RES: $2.12SUP: $1.31SMA50: $1.87SMA200: $1.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LXRX Butterfly Map → + Track LXRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LXRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LXRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LXRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LXRX)

Health Care Rank #922 of 1016 ⚔️ ABUS vs LXRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LXRX vs. ABUS, IMMX, ANL, BCAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexicon Pharmaceuticals Inc. (LXRX) ranks #922 by composite RQD confidence (27/100, grade E) and #408 by equity capitalization ($658.5M). Within this direct 5-issuer industry benchmark cohort, LXRX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with LXRX at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LXRX ACTIVE Lexicon Pharmaceuticals Inc.	E	27/100	—	96.0%	-31.5%	-4.05%	$658.5M	Benchmark Subject
ABUS Arbutus Biopharma Corporation	E	18/100	—	—	-35.0%	-1.64%	$656.0M	/abus-vs-lxrx →
IMMX Immix Biopharma Inc.	E	29/100	—	—	-35.0%	-3.76%	$661.6M	/immx-vs-lxrx →
ANL Adlai Nortye Group Ltd.	D	47/100	—	—	—	-7.10%	$662.0M	/anl-vs-lxrx →
BCAX Bicara Therapeutics Inc.	E	30/100	—	—	-35.0%	-6.17%	$643.9M	/bcax-vs-lxrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001062822

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lexicon Pharmaceuticals Inc. (LXRX) reported GAAP revenue of $49.8M (+729.9% vs. FY2024 revenue of $6.0M , and +4386.8% cumulative change since FY2023) , GAAP net income of -$50.3M, operating cash flow of -$67.9M, and free cash flow of -$67.9M (+62.3% YoY). On the balance sheet, LXRX closed FY2025 with $185.0M in total assets against $49.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$49.8M	-$50.3M	-$67.9M	-$67.9M	$185.0M	$49.4M
FY2024 (FY)	2024-12-31	$6.0M	-$200.4M	-$178.8M	-$179.8M	$298.4M	$100.3M
FY2023 (FY)	2023-12-31	$1.1M	-$177.1M	-$161.9M	-$161.9M	—	—

3. LXRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LXRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LXRX compare to ABUS and IMMX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LXRX?

Where is LXRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LXRX last traded at $1.42 (-4.05% on volume of 2,444,226 shares), positioning the stock -24.06% below its 50-day simple moving average ($1.87) and -24.87% below its 200-day simple moving average ($1.89). Across its 52-week range of $1.10 to $2.68, LXRX sits at the 20.3% percentile with a 14-day RSI of 36.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.26 to $1.58).

LXRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LXRX's 12-month stock price target?

Lexicon Pharmaceuticals Inc. (LXRX) carries a 12-month consensus base price target of $1.22 (-14.1% from $1.42), with a bull-case target of $2.81 and a bear-case floor of $0.95.

Is LXRX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates LXRX E (Strong Sell — SELL) with an RQD Confidence score of 27/100.

Direct Sub-Reports: LXRX RQD Cockpit LXRX 12M Forecast LXRX Earnings & Move LXRX Dividends & DRIP LXRX Insiders & 13F LXRX Whale Options LXRX Profit Sankey LXRX News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LXRX — Lexicon Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LXRX scores 27 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 4 / 20. This is the weakest pillar and reflects ROIC of -31.5% and an FCF yield of -10.3%. For a prospective investor, this means the business is currently consuming capital rather than generating it, so any upside depends on a future turn in cash generation that the source data does not show.
Whale 13F Flow: 3 / 20. Scored on institutional accumulation and options positioning. The low score indicates weak smart-money conviction in the current data set. Specific 13F holdings are not available in source data.
Insider Conviction: 3 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. The low score suggests insider activity is not providing a supportive signal. Specific transaction detail is not available in source data.
Macro Regime Fit: 6 / 20. Based on a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, so it offers no defensive cushion in a downturn and no outsized leverage in an upturn.
Forensic Balance Sheet: 11 / 20. The highest-scoring pillar, citing an Altman Z-Score of 2.5, a Piotroski F-Score of 5 out of 9, and a Debt/Equity ratio of 0.46. This pillar is the most supportive, though still moderate.

Taken together, the rating points to a company with negative operating economics and cash burn, where the balance sheet is the main mitigating factor. The implication for a prospective investor is that valuation cannot be anchored to current earnings or cash flow, since neither is positive in the source data, and the risk of further capital needs is a central consideration.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$49.8M	$-48.9M	$-50.3M	N/A	$-67.9M	$34.3M	$49.4M
FY 2024	$6.0M	$-197.1M	$-200.4M	N/A	$-179.8M	$66.7M	$100.3M
FY 2023	$1.1M	$-171.8M	$-177.1M	N/A	$-161.9M	N/A	N/A

Per the SEC financials, every reported period shows an operating loss and net loss, with FCF negative in each year. Revenue rose from $1.1M in FY 2023 to $49.8M in FY 2025, while net income moved from $-177.1M to $-50.3M, indicating narrowing losses in absolute terms. Per the market data, gross margin is 96%, but operating margin and net margin are both -60%, and ROIC is -31.5%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5 out of 9. Cash fell from $66.7M to $34.3M while debt declined from $100.3M to $49.4M across FY 2024 to FY 2025, and the Debt/Equity ratio is 0.46.

Recent Catalysts & News Wire Analysis

Per the recent news feed, LXRX appears across several market-wire items:

A Q2 2026 earnings call transcript is referenced from Benzinga.
Cantor Fitzgerald reaffirmed a Buy rating, per The Globe and Mail headline.
A research publication on sotagliflozin's biological effects in cardiovascular disease was announced, per MarketScreener.
A Q2FY26 results item from scanx.trade is flagged RED under the RISK WATCH category, headlined as a net loss widening to $31.8 million.

Per the Butterfly Supply-Chain Graph, a LIQUIDITY_TAILWIND signal is bullish with a severity score of 91 and a Macro Tailwind Score of 92/100. The signal states a 2.97x True Net Liquidity beta with an r of -0.19 and attributes the tailwind to the current Fed/TGA/RRP liquidity print of $5,746B. The signal is macro-driven and does not reflect company-specific fundamentals. Note the tension: the macro signal is bullish while the RQD rating and RED-flagged risk item are bearish on fundamentals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE and no butterfly links are provided, so no upstream or downstream dependencies can be mapped from the source data. Sector correlations beyond the stated Health Care / Biotechnology classification are not available in source data. The main 2nd-order channel visible in the data is liquidity sensitivity: the macro signal implies that LXRX's price responds to shifts in net liquidity, so a tightening of liquidity conditions, as reflected in the Fed, TGA, and RRP components, would be a ripple risk. Investors should also watch the high-yield spread, which the signal cites at +2 bps, as an indicator of financing conditions for cash-consuming issuers.

Open Questions

What specific products or revenue sources generate the FY 2025 revenue of $49.8M, and how durable is that revenue?
What is the company's path to positive operating cash flow, given operating margin of -60% and FCF of $-67.9M in FY 2025?
What cash runway exists against the $34.3M cash balance at the current burn rate?
What is the basis for the Cantor Fitzgerald Buy reaffirmation, and is there a price target?
What drove the widening net loss reported in the Q2FY26 results, and what do the RED-flagged risk items specifically describe?

LXRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lexicon Pharmaceuticals Inc. (LXRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LXRX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 5h ago

Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11h ago

Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Lexicon Pharmaceuticals (NASDAQ:LXRX

Benzinga report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 14h ago

Cantor Fitzgerald Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)

The Globe and Mail report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 17h ago

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

www.marketscreener.com report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH scanx.trade • 20h ago

Lexicon Pharmaceuticals Q2FY26 Results: Net loss widens to $31.8 million

scanx.trade report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 23h ago

Cantor sets USD 8.00 target for Lexicon Pharmaceuticals stock

ad-hoc-news.de report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

Yahoo Finance report covering Lexicon Pharmaceuticals Inc. (LXRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10d ago

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial o

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LXRX Bull vs. Bear Conversation Board — What's Your Call at $1.42?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LXRX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.30 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LXRX (E • RQD 27/100) a Buy at $1.48?

Welcome to the LXRX (Lexicon Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.23 (-16.9%)

Spot @ $1.48

Pump the brakes on LXRX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LXRX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Lexicon Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.70 (+14.9%)

Spot @ $1.48

LXRX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LXRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.48 (52-wk range $1.10 - $2.68), any beat on forward guidance forces shorts and underweight funds to chase.